Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
64 participants
OBSERVATIONAL
2016-03-31
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Serum Ferritin Concentration and Fetal MCA Doppler as Predictors for Preterm Delivery
NCT02420743
Prediction of Late Fetal Growth Restriction Using Cerebroplacental Ratio
NCT04640467
The Oral Iron on the Prevention of Iron Deficiency Anemia in Obese Pregnant
NCT04101461
Questionnaire About Risk Factors of Iron Deficiency Anemia in Pregnancy
NCT06761352
The Effect of Maternal Iron Deficiency Anemia on Fetal Hemodynamic and Neonatal Outcome
NCT04016922
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There are two general patterns of growth abnormalities: symmetric and asymmetric. Symmetric growth inhibition arises during the first half of gestation, when fetal growth occurs primarily through cellular division and produces an undersized fetus with fewer cells of normal size. Asymmetric growth inhibition occurs during the second half of gestation and is usually the consequence of an inadequate availability of substrates for fetal metabolism. To prevent the previously mentioned complications of IUGR, it is important to establish markers which can identify pregnancies at risk of IUGR early enough. Recently several studies have highlighted the role of many bio-molecules as markers for IUGR like leptin, adiponectin, endothelin-1, lactate dehydrogenase, s-endoglin, pregnancy associated plasma protein, metastin. Apart from being expensive, laboratories at majority of centers are not equipped with facilities of measurement of these markers. Measurement of maternal serum ferritin has also been used as a predictive marker for increased risk of IUGR in one previous study on a limited number (seventeen) of cases. Ferritin is an intracellular protein consisting of 24 heavy and light sub-units surrounding a core that can store up to 4,500 iron atoms. The two sub-units are highly conserved during evolution, but only the heavy sub-unit has ferroxidase activity. Ferritin is released by infiltrating leukocytes, in response to acute and chronic infection. Ferritin as an acute phase reactant is well known for its intracellular iron sequestration and storage abilities during immune activation. Serum ferritin concentration is positively correlated with the amount of total body iron stores in the absence of inflammation. Serum ferritin is considered a valuable bio-marker for body iron status in healthy subjects.Iron deficiency has its known deleterious effect in pregnancy but iron loading may be associated with oxidative damage to cells and tissues. It has been shown in various studies that lower level of transferritin receptor expression in placenta is associated with preeclampsia and IUGR. This can lead to decrease extraction of iron by placenta from maternal serum leading to increase maternal serum ferritin. This fetal iron deficiency leads to increase in fetal corticotropins and fetal cortisol, causing inhibition of fetal growth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 case
This group will include 32 pregnant females whose fetuses show intrauterine growth restriction at full term ( the 32 neonates with birth weight less than 10th percentile for corresponding gestational age will be included as small for gestational age and the investigator will thaw their maternal frozen samples for detection of serum ferritin level)
No interventions assigned to this group
Group 2 control
This group will include at least 32 pregnant females whose fetuses are appropriate for gestational age at full term ( the 32 neonates with birth more than or equal to the 10th percentile for corresponding gestational age will be included as average for gestational age and the investigator will thaw their maternal frozen samples for detection of serum ferritin level)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pregnant with singleton intrauterine pregnancy
* 30th-32nd weeks of gestation
Exclusion Criteria
* Patients with history of iron supplementation, Clinical and/or laboratory evidence of hepatic, renal, hematologic, cardiovascular abnormalities.
* History of acid-peptic disorders, esophagitis, or hiatal hernia.
* Family history of thalassemia, sickle cell anemia, or malabsorption syndrome.
* Antepartum hemorrhage.
* Allergies to milk proteins / hypersensitivity to iron preparations.
* Patients with acute infection, positive CRP, raised TLC count.
* Congenital malformation and fetuses with chromosomal or genetic syndrome.
* Recent blood transfusion.
* Refusal to participate in the study.
* BMI \<18.
* Placental abnormalities like velamentous insertion.
* Multiple pregnancies.
* Smoking during pregnancy
* Preterm births.
20 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Ain Shams Maternity Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shaimaa Mahmoud salem
principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hassan A Bayoumyi, MD
Role: STUDY_CHAIR
Ain Shams University
Sherif A Ashoush, MD
Role: STUDY_DIRECTOR
Ain Shams University
Haitham AM ElSabaa, MD
Role: STUDY_DIRECTOR
Ain Shams University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams Maternity Hospital
Cairo, Cairo Governorate, Egypt
outpatient clinics in the Obstetrics and Gynecology Department Ain Shams Maternity Hospital
Cairo, Cairo Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Arosio P, Ingrassia R, Cavadini P. Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta. 2009 Jul;1790(7):589-99. doi: 10.1016/j.bbagen.2008.09.004. Epub 2008 Sep 26.
Bindal N, Godha Z, Kohli R, Kadam VK. Role of maternal serum ferritin as a predictive marker in intrauterine growth restriction. Int J Reprod Contracept Obstet Gynecol. 2015 Jun;4(3):804-808
Milman N. Iron Deficiency and Anaemia in Pregnant Women in Malaysia - Still a Significant and Challenging Health Problem. J Preg Child Health 2015, 2:3
Moh W, Graham JM Jr, Wadhawan I, Sanchez-Lara PA. Extrinsic factors influencing fetal deformations and intrauterine growth restriction. J Pregnancy. 2012;2012:750485. doi: 10.1155/2012/750485. Epub 2012 Jul 19.
Murki S and Sharma D. Intrauterine Growth Retardation - A Review Article. Murki and Sharma, J Neonatal Biol 2014, 3:3
Nandini M D, Shetty HV, Rupakala BV, Usha S M R, Priyadarshini KS, Manjula HS and Victoria Ksh. Study of serum ferritin levels in preterm labor. International Journal of Recent Trends in Science and Technology, ISSN 2277-2812 E-ISSN 2249-8109, Volume 14, Issue 2, 2015 pp 477-480
Muhammad T, Khattak AA, Shafiq-ur-Rehman, Khan MA, Khan A, Khan MA. Maternal factors associated with intrauterine growth restriction. J Ayub Med Coll Abbottabad. 2010 Oct-Dec;22(4):64-9.
Višnjevac N, Segedi LM, Ćurčić A, Višnjevac J, Dragan Stajić. Blood ferritin levels in pregnant women and prediction of the development of fetal intrauterine growth restriction. J Med Biochem. 2011;30:m317-22
Wang CN, Chang SD, Peng HH, Lee YS, Chang YL, Cheng PJ, Chao AS, Wang TH, Wang HS. Change in amniotic fluid levels of multiple anti-angiogenic proteins before development of preeclampsia and intrauterine growth restriction. J Clin Endocrinol Metab. 2010 Mar;95(3):1431-41. doi: 10.1210/jc.2009-1954. Epub 2010 Jan 15.
Zhang S, Regnault TR, Barker PL, Botting KJ, McMillen IC, McMillan CM, Roberts CT, Morrison JL. Placental adaptations in growth restriction. Nutrients. 2015 Jan 8;7(1):360-89. doi: 10.3390/nu7010360.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Individual Participant Data Set
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Ross MG. Fetal growth restriction, 2008
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHMS1985
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.